CA Patent

CA2471578A1 — Xanthene-carboxylic acid esters of tropenol and scopine as m3 antagonists, method for producing the same and use thereof as medicaments

Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2003-08-07 · 23y expired

What this patent protects

The invention relates to novel xanthene-carboxylic acid esters of formula 1: (see formula 1), in which X is an anion with a single negative charge; A is a double-bonded group; R is optionally substituted alkyl, hydroxy or fluorine; R1 and R2 are identical or different and are…

USPTO Abstract

The invention relates to novel xanthene-carboxylic acid esters of formula 1: (see formula 1), in which X is an anion with a single negative charge; A is a double-bonded group; R is optionally substituted alkyl, hydroxy or fluorine; R1 and R2 are identical or different and are optionally substituted alkyl or together are an alkylene bridge; R3, R4, R3' , R4' are identical or different and are optionally substituted alkyl, hydrogen, hydroxy, cyano, nitro or halogen. The invention also relates to a method for producing said esters and to the use thereof as medicaments.

Drugs covered by this patent

Patent Metadata

Patent number
CA2471578A1
Jurisdiction
CA
Classification
Expires
2003-08-07
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.